Sales Call

Continued good momentum despite China declining low-single digit due to a tough comparative Volume /mix Pain Relief – Double digit decline mainly due to challenging Fenbid comparative in China in Q1 2023 when revenue more than doubled Strong Q1 organic profit growth 23.1% 24.2% +220bps (30)bps (80)bps 12 1. Reconciliation of IFRS to Adjusted results can be found in the Appendix 2. Net M&A: disposal of Lamisil and includes the impact of Manufacturing Service Agreements (MSAs) 3. Refers to Organic. Definition ...